Clinical trialNCT05053971RecruitingPhase 1/PHASE2Interventional

Testing A New Anti-cancer Drug Combination, Entinostat and ZEN003694, for Advanced and Refractory Solid Tumors

SponsorNational Cancer Institute (NCI)Enrollment49Advanced Malignant Solid NeoplasmLocally Advanced Pancreatic CarcinomaMetastatic Pancreatic CarcinomaRefractory Malignant Solid NeoplasmRefractory Pancreatic CarcinomaStage II Pancreatic Cancer AJCC v8+3 more conditions

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This phase I/II trial tests the safety, side effects, and best dose of entinostat and ZEN003694 in treating patients with solid tumors that have spread to other places in the body (advanced) or does not respond to treatment (refractory). Entinostat is in a class of drugs called histone deacetylase (HDAC) inhibitors. It may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. ZEN003694 is an inhibitor of a family of proteins called the bromodomain and extra-terminal (BET). It may prevent the growth of tumor cells that over produce BET protein. This trial aims to test the safety of combination therapy with entinostat and ZEN003694 in treating patients with advanced or refractory solid tumors.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Patricia M LoRusso
Yale University Cancer Center LAO
Principal InvestigatorKOL profile →
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

3 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

Yale University
New Haven, Connecticut, United States
Patricia M. LoRusso
Recruiting
Uf Health Cancer Institute - Gainesville
Gainesville, Florida, United States
Thomas J. George
Recruiting
University of Oklahoma Health Sciences Center
Oklahoma City, Oklahoma, United States
Abdul Rafeh Naqash
Recruiting

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

BET Bromodomain Inhibitor ZEN-3694 →Entinostat

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 16 Nov 2022
Primary completion: 1 Jul 2027
Completion: 1 Jul 2027
Last update posted: 15 Jul 2026
Registered enrollment: 49
Registry id: NCT05053971

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.